


RESEARCH ARTICLE

Open Access



Development of a high-affinity anti-bovine PD-1 rabbit–bovine chimeric antibody using an efficient selection and large production system

Tomohiro Okagawa¹, Satoru Konnai^{1,2,3*} , Shinya Goto², Yamato Sajiki², Otgontuya Ganbaatar², Kei Watari², Hayato Nakamura², Cai-Xia Wang⁴, Taro Tachibana^{4,5}, Yukinari Kato^{6,7}, Yayoi Kameda⁸, Junko Kohara⁹, Nobuhiro Terasaki¹⁰, Manabu Kubota¹⁰, Akira Takeda¹⁰, Hirofumi Takahashi¹⁰, Yasuhiko Suzuki^{1,3,8,11}, Naoya Maekawa¹, Shiro Murata^{1,2} and Kazuhiko Ohashi^{1,2,12}

Abstract

Immune checkpoint molecules PD-1/PD-L1 cause T-cell exhaustion and contribute to disease progression in chronic infections of cattle. We established monoclonal antibodies (mAbs) that specifically inhibit the binding of bovine PD-1/PD-L1; however, conventional anti-PD-1 mAbs are not suitable as therapeutic agents because of their low binding affinity to antigen. In addition, their sensitivity for the detection of bovine PD-1 is low and their use for immunostaining PD-1 is limited. To address these issues, we established two anti-bovine PD-1 rabbit mAbs (1F10F1 and 4F5F2) and its chimeric form using bovine IgG1 (Boch1D10F1), which exhibit high binding affinity. One of the rabbit mAb 1D10F1 binds more strongly to bovine PD-1 compared with a conventional anti-PD-1 mAb (5D2) and exhibits marked inhibitory activity on the PD-1/PD-L1 interaction. In addition, PD-1 expression in bovine T cells could be detected with higher sensitivity by flow cytometry using 1D10F1. Furthermore, we established higher-producing cells of Boch1D10F1 and succeeded in the mass production of Boch1D10F1. Boch1D10F1 exhibited a similar binding affinity to bovine PD-1 and the inhibitory activity on PD-1/PD-L1 binding compared with 1D10F1. The immune activation by Boch1D10F1 was also confirmed by the enhancement of IFN- γ production. Finally, Boch1D10F1 was administered to bovine leukemia virus-infected cows to determine its antiviral effect. In conclusion, the high-affinity anti-PD-1 antibody developed in this study represents a powerful tool for detecting and inhibiting bovine PD-1 and is a candidate for PD-1-targeted immunotherapy in cattle.

Keywords Monoclonal antibodies, programmed death-1, cattle, antibody production

Handling editor: Tom McNeilly

*Correspondence:

Satoru Konnai

konnai@vetmed.hokudai.ac.jp

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Programmed death-1 (PD-1) is an immune checkpoint molecule that interacts with its ligand PD-ligand 1 (PD-L1) to cause the functional exhaustion of T cells, which is evident through the loss of effector function by inhibiting T-cell receptor (TCR) signaling [1–3]. During chronic infection, PD-1 is upregulated on T cells as a result of persistent stimulation via TCR, co-receptors, and cytokines [4]. In cattle, the functional exhaustion of T cells is caused by the upregulation of the PD-1/PD-L1 pathway and results in disease progression during chronic infections, such as bovine leukemia virus (BLV) infection [5–8]. BLV is a retrovirus which infects bovine B cells and develops into a lifelong infection in cattle. It can also result in an aggressive lymphoma, known as enzootic bovine leukosis (EBL), in 1–5% of the infected cattle after a long latent period [9]. In previous studies, we developed anti-bovine PD-1 and anti-bovine PD-L1 rat-bovine chimeric antibodies (chAbs) in a mammalian expression system and tested their antiviral effects in clinical studies using BLV-infected cattle [10–12]. Blockade of the binding of PD-1/PD-L1 by these chAbs restored T-cell function and exerted antiviral effects in the BLV-infected cattle [11, 12].

Although the antiviral effect was observed by treatment with anti-bovine PD-1 rat-bovine chAb (Boch5D2), the binding affinity of Boch5D2 to bovine PD-1 was relatively low compared with that of commercial anti-human PD-1 blocking antibodies for immunotherapy [13, 14]. Recently, novel therapeutic antibodies with higher binding affinities to PD-1 have been developed to enhance the clinical benefit of immunotherapy in humans [13, 14]. In addition, the application of immunostaining for flow cytometry using anti-bovine PD-1 rat mAb (5D2) established in a previous study [7] was also limited because of its low binding affinity [10]. Indeed, PD-1 expression was detectable by flow cytometry using 5D2 only in T cells of the cattle experiencing a robust stimulation by antigens during chronic infection [8, 15–17]. To address the mechanism of T-cell exhaustion mediated by PD-1 in various bovine diseases, a novel mAb capable of detecting bovine PD-1 with high sensitivity in the flow cytometric analysis is required.

Mice and rats are widely used for immunization to generate mAbs; however, the use of rabbits for the mAb development has attracting interest because of their unique and highly distinctive antibody repertoire, which exhibits high-affinity, specificity, and diversity [18]. Indeed, previous studies have been succeeded in developing high-affinity mAbs to several antigens using rabbits [19–21]. These findings prompted us to establish a rabbit mAb against bovine PD-1.

Gram-scale quantities of antibody are required for clinical trials of therapeutic antibodies in adult cattle. We have established an expression system for large amounts of antibody using a mammalian cell line and an engineered expression plasmid with a DHFR marker for efficient selection of transfected cells and a ubiquitous chromatin opening element (UCOE) to reduce DNA methylation in the transgene promoter [22, 23]. We applied this system for the large production of chAb for a clinical trial in cattle.

In this study, we generated an anti-bovine PD-1 rabbit mAb (1D10F1) and rabbit-bovine chAb (Boch1D10F1) which exhibit high-affinity to bovine PD-1. The biochemical properties of these antibodies were compared with anti-bovine PD-1 rat mAb (5D2) and chAb (Boch5D2) which were established previously [7, 10]. Accordingly, mass production of Boch1D10F1 was achieved and administration of Boch1D10F1 to BLV-infected cattle was conducted to evaluate the antiviral effects of this high-affinity antibody.

Materials and methods

Generation of anti-bovine PD-1 rabbit mAbs

A rabbit was immunized with recombinant bovine PD-1-Ig fusion protein [24] in TiterMax Gold Adjuvant (Sigma–Aldrich, St. Louis, MO, USA). Lymphocytes were collected from the immunized rabbit 3 weeks later, were fused with SP2 myeloma cells. Culture supernatants from heterohybridomas [25, 26] were screened using ELISA with recombinant polyhistidine-tagged bovine PD-1 protein (BoPD-1-His) [10] and horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (H+L) antibody (Jackson ImmunoResearch, West Grove, PA, USA). The hybridomas that tested positive in ELISA were cloned by limiting dilution. Culture supernatant of cultivated clones were tested again by ELISA against BoPD-1-His and total RNA was isolated from the positive clones of hybridomas using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. cDNAs were synthesized from the RNA samples with SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity DNA Polymerase (Thermo Fisher Scientific). The gene encoding variable regions of heavy and light chains of antibody (VH and VL) were amplified using KOD-Plus-Neo DNA Polymerase (Toyobo, Osaka, Japan) and gene specific primers. The amplicons were cloned into pCAGGS [27] with the nucleotides encoding constant regions of heavy and light chains (CH and CL) of rabbit IgG and sequenced by Eurofins Genomics (Tokyo, Japan). HEK293T cells were transfected with the expression plasmids and grown in fetal bovine serum (FBS)-free D-MEM medium (Fuji-film Wako Pure Chemical, Osaka, Japan). The culture

supernatants were tested by ELISA against bovine PD-1 as shown above. The supernatants from two clones (1D10F1 and 4F5F2) were positive in ELISA and further tested in the following screening test using purified antibodies.

Expression and purification of anti-bovine PD-1 rabbit mAbs

Transient cell lines expressing anti-bovine PD-1 rabbit mAbs were established using the Expi293 Expression System (Thermo Fisher Scientific). Briefly, Expi293F cells were transfected with the expression plasmids, pCAGGS-1D10F1-VHCH and pCAGGS-1D10F1-VLCL or pCAGGS-4F5F2-VHCH and pCAGGS-4F5F2-VLCL, using Expifectamine (Thermo Fisher Scientific) and cultured with shaking in Expi293 Medium (Thermo Fisher Scientific) at 37 °C and 125 rpm with 8% CO₂ for 7 days. For negative control antibodies, cells were transfected with a combination of pCAGGS-1D10F1-VHCH and pCAGGS-4F5F2-VLCL (1H4L) or the other combination (4H1L). Antibodies were purified from the culture supernatants by affinity chromatography with an Ab-Capcher ExTra (ProteNova) and the buffer was exchanged with phosphate-buffered saline (PBS) by size exclusion chromatography using PD-10 Desalting Column (GE Healthcare). The concentration of Boch5D2 was measured by ultraviolet (UV) absorbance at 280 nm with a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific).

Expression and purification of anti-bovine PD-1 bovine-rabbit chAb

The nucleotide sequences of the VH and VL genes of 1D10F1 were combined with the constant regions of bovine IgG₁ (GenBank accession number X62916) with reduced F_c-mediated effector functions (IgG₁ ADCC-) [10] and bovine Ig lambda (GenBank accession number X62917), respectively. In selecting the subclasses of the constant region, the dominant subclasses in bovine immunoglobulins (IgG1 and Igλ) were chosen [28, 29]. The resulting sequences were modified according to the optimal codon usage of the Chinese hamster, synthesized (GenScript), and cloned into the expression vectors, pDC62c5-U533, pDC61, and pNC32c5-U533 [23].

CHO DG44 cells (a *dhfr*-deficient CHO cell line) were transfected with the expression vectors and cloned by limiting dilution in CD OptiCHO medium (Thermo Fisher Scientific) supplemented with 2 mM GlutaMAX-I (Thermo Fisher Scientific). For the selection of cells transfected with pNC32c5-U533, 800 μg/mL of G418 sulfate (Enzo Life Sciences) were added to the medium. After 3 weeks, the cloned cells were screened for their ability to produce Boch1D10F1 using an enzyme-linked immunosorbent assay (ELISA) with horseradish

peroxidase (HRP)-conjugated anti-bovine IgG Fc rabbit polyclonal antibody (Rockland Immunochemicals) as previously described [24]. Boch1D10F1 was produced by shaking the established cell lines in Dynamis Medium (Thermo Fisher Scientific) with EfficientFeed B+ AGT Supplement (Thermo Fisher Scientific) at 37 °C with 5% CO₂ for 14 days. Live and dead cells were counted with a Countess Automated Cell Counter (Thermo Fisher Scientific). The concentration of Boch1D10F1 in the culture supernatant was determined using a bovine IgG ELISA as described above.

Purification of Boch1D10F1 from the culture supernatant was performed by affinity chromatography with an Ab-Capcher ExTra (ProteNova) and PD-10 Desalting Column (GE Healthcare) as described above. The concentration of the purified Boch1D10F1 was measured by UV absorbance at 280 nm with a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific). The purity of Boch1D10F1 was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or nonreducing conditions on a SuperSep Ace 5%–20% gradient polyacrylamide gel (Fujifilm Wako Pure Chemical) with 2×Laemmli Sample Buffer (Bio-Rad, Hercules, CA, USA). The Precision Plus Protein Dual Standard (Bio-Rad) was used as a molecular weight size marker and the proteins were visualized with Quick-CBB (Fujifilm Wako Pure Chemical).

Binding assay of anti-bovine PD-1 antibodies

To confirm the binding activity of the anti-bovine PD-1 rabbit mAbs and chAb (Boch1D10F1) to bovine PD-1 protein, flow cytometry was performed using myc-tagged bovine PD-1-expressing CHO DG44 cells (BoPD-1-myc cells) [7]. Briefly, BoPD-1-myc cells were incubated with the purified mAbs (1D10F1, 4F5F2, 1H4L, or 4H1L), anti-bovine PD-1 rat mAb (5D2) [7], rat IgG_{2a} isotype control (R35-95, BD Biosciences), Boch1D10F1, or bovine IgG control (Sigma-Aldrich) at room temperature for 30 min. The cells were then washed with PBS supplemented with 1% bovine serum albumin (BSA; Sigma-Aldrich) and labeled with Alexa Flour 647-conjugated anti-rabbit IgG (H+L) goat F(ab')₂ (Thermo Fisher Scientific), APC-conjugated anti-rat immunoglobulin antibody (Southern Biotech) or APC-conjugated anti-bovine IgG Fc goat antibody (Jackson ImmunoResearch) at room temperature for 30 min. Finally, the cells were washed and analyzed immediately using FACS Verse (BD Biosciences).

To evaluate the detection sensitivity and specificity of anti-bovine PD-1 rabbit mAbs to PD-1 protein in bovine lymphocytes, multicolor flow cytometric analysis was performed using bovine leukocytes isolated from fresh blood samples. To prevent nonspecific reactions of staining antibodies, leukocytes were incubated

in PBS containing 10% goat serum (Sigma–Aldrich) at room temperature for 15 min. The cells were stained with anti-bovine PD-1 rabbit mAb (1D10F1 or 4F5F2), rabbit IgG controls (1H4L), anti-bovine PD-1 rat mAb (5D2) [7], or rat IgG_{2a} isotype control (R35-95, BD Biosciences) for 30 min at room temperature. After washing with 1% BSA-PBS, the cells were labeled with Alexa Fluor 647-conjugated anti-rabbit IgG (H + L) goat F(ab')₂ (Thermo Fisher Scientific) or APC-conjugated anti-rat immunoglobulin antibody (Southern Biotech) for 30 min at room temperature with a cocktail of staining antibodies, including PerCp/Cy5.5-conjugated anti-bovine CD3 mAb (MM1A; Washington State University Monoclonal Antibody Center), FITC-conjugated anti-bovine CD4 mAb (CC8; Bio-Rad), PE-conjugated anti-bovine CD8 mAb (CC63, Bio-Rad), APC/Cy7-conjugated anti-TCR1-N24 mAb (GB21A; Washington State University Monoclonal Antibody Center), and PE/Cy7-conjugated anti-bovine IgM mAb (IL-A30; Bio-Rad). The mAbs MM1A, GB21A, and IL-A30 were conjugated with each fluorochrome using Lightning-Link Conjugation Kits (Innova Biosciences). Finally, the cells were washed and analyzed by FACS Verse (BD Biosciences).

Surface plasmon resonance analysis

To assess the binding affinity of 1D10F1, 4F5F2, and Boch1D10F1 to bovine PD-1, surface plasmon resonance (SPR) analysis was performed using the Biacore System (GE Healthcare) with BoPD-1-His as described previously [10]. SPR measurements were performed using a CM5 sensor chip (GE Healthcare) immobilized with BoPD-1-His and 1D10F1, 4F5F2, 5D2, and Boch1D10F1 on a Biacore X100 or Biacore 3000 instrument (GE Healthcare) at 25 °C. The kinetic constant of each antibody was determined by fitting with a 1:1 kinetic binding model.

Blockade assay of PD-1/PD-L1 binding

To confirm the ability of 1D10F1, 4F5F2, and Boch1D10F1 to block PD-1/PD-L1 binding, biotinylated BoPD-1-Ig (5 µg/mL) [24] was incubated with various concentrations (0.39 to 50 µg/mL) of 1D10F1, 4F5F2, and Boch1D10F1 at 37 °C for 30 min. The incubated BoPD-1-Ig proteins were incubated with bovine PD-L1-EGFP-expressing CHO DG44 cells (BoPD-L1-EGFP cells) [24] at 37 °C for 30 min. BoPD-1-Ig bound to BoPD-L1-EGFP cells was labeled with APC-conjugated streptavidin (BioLegend) at room temperature for 30 min, washed with PBS, and analyzed by FACS Verse (BD Biosciences). Rat IgG_{2a} isotype control (R35-95, BD Biosciences), rabbit IgG controls (1H4L and 4H1L), and bovine IgG₁ control (Bethyl Laboratories) were used as negative controls.

Immune activation assay by Boch1D10F1

To analyze immune activation by Boch1D10F1, peripheral blood mononuclear cell (PBMC) cultivation assay was conducted as previously described with some modifications [8]. PBMCs were isolated from the peripheral blood of BLV-infected cattle by density gradient centrifugation using Percoll (GE Healthcare), washed three times with PBS, and suspended in RPMI1640 Medium (Sigma–Aldrich) supplemented with 10% heat-inactivated FBS (Thermo Fisher Scientific), 200 IU/mL of penicillin, 200 µg/mL of streptomycin, and 0.01% L-glutamine (Thermo Fisher Scientific). PBMCs were cultured with 20 µg/mL of Boch1D10F1, anti-bovine PD-1 rat-bovine chAb (Boch5D2) [10], or bovine IgG control (Sigma–Aldrich) in the presence of 2% heat-inactivated supernatant from BLV-infected fetal lamb kidney cells (FLK-BLV) at 37 °C in 5% CO₂ for six days. Culture supernatants were then harvested and IFN-γ concentrations in the supernatants were determined using a bovine IFN-γ ELISA (Mabtech) performed in duplicate according to the manufacturer's protocol.

Evaluation of the antiviral effect of Boch1D10F1 treatment in BLV-infected cattle

To confirm the antiviral effects of Boch1D10F1 in cattle, the administration of Boch1D10F1 was performed in cattle naturally infected with BLV ($n=6$, Holstein, female; Additional file 1) in animal facilities at the Animal Research Center, Agricultural Research Department, Hokkaido Research Organization (Shintoku, Hokkaido, Japan) and Faculty of Veterinary Medicine, Hokkaido University (Sapporo, Hokkaido, Japan). BLV infection was confirmed by the detection of anti-BLV antibodies in plasma using a commercial ELISA kit (JNC, Tokyo, Japan) and by the detection of BLV provirus in DNA using real-time PCR as described previously [10]. The number of lymphocytes in blood samples was counted using an automated hematology analyzer (Celltac α; Nihon Kohden, Tokyo, Japan). BLV-infected cattle were classified as aleukemic (AL) or persistent lymphocytosis (PL) based on the lymphocyte counts as follows: AL < 8000 cells/µL; PL > 8000 cells/µL.

Four BLV-infected cattle (AL2, AL3, PL2, and PL3) were intravenously administered 1 mg/kg (AL2 and AL3) or 2 mg/kg (PL2 and PL3) of purified Boch1D10F1 diluted in saline (Additional file 1). Two of the animals (AL3 and PL3) were also administered 0.5 mg/kg of meloxicam (Metacam; Boehringer Ingelheim, Ingelheim, Germany) subcutaneously three times at seven-days intervals (Additional file 1). The other two animals (AL1 and PL1) did not receive any treatment and were used as negative controls (Additional file 1). This

animal experiment was approved by the Ethics Committee of the Animal Research Center, Agricultural Research Department, Hokkaido Research Organization (approval #1703) and the Ethics Committee of the Faculty of Veterinary Medicine, Hokkaido University (Approval #17-0024).

To determine proviral loads in the peripheral blood, the BLV *tax* gene was measured in genomic DNA by quantitative real-time PCR using the Cycleave PCR Reaction Mix (Takara Bio) and a Probe/Primer Mix for BLV (Takara Bio) with a LightCycler 480 System II (Roche Diagnostics) as described previously [10]. Each DNA sample was tested in triplicate. Genomic DNA was extracted from PBMCs with the Wizard Genomic DNA Purification Kit (Promega) and the concentration of DNA was measured by UV absorbance at 260 nm with a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific).

Statistical analysis

All statistical tests were performed with GraphPad Prism 6 software (GraphPad Software Inc.). Differences were considered statistically significant at $p < 0.05$.

Results

Establishment and characterization of anti-bovine PD-1 rabbit mAbs

Supernatants containing rabbit mAbs from two hybridoma clones were established using lymphocytes from a rabbit immunized BoPD-1-Ig and showed specific binding to BoPD-1-His protein in ELISA. These anti-bovine PD-1 rabbit mAbs were purified and tested for their binding affinity to bovine PD-1 protein by SPR analysis using a Biacore instrument. 1D10F1 and 4F5F2 showed higher affinities for PD-1 compared with 5D2, with K_D values of 1.11 ± 0.07 , 2.85 ± 0.50 , and 0.12 ± 0.04 nM, respectively (Table 1). In particular, 1D10F1 exhibited the highest association constant (k_a) compared with the other mAbs (Table 1). The binding ability and specificity

to bovine PD-1-expressing cells (BoPD-1-myc cells) were then tested by flow cytometry. Both anti-PD-1 rabbit mAbs (1D10F1 and 4F5F2) bound to BoPD-1-myc cells in a dose-dependent manner (Figure 1A) but not to mock cells (Additional file 2). Negative controls of rabbit mAbs (1H4L and 4H1L) did not bind to BoPD-1-myc cells at any tested concentrations (Figure 1A). 1D10F1 exhibited a stronger fluorescent intensity compared with 4F5F2 and anti-PD-1 rat mAb (5D2), which was established in our previous study (Figure 1A).

To determine the reactivity of anti-PD-1 rabbit mAb (1D10F1) to PD-1 naturally expressed on bovine T cells, the surface expression of PD-1 was analyzed in T-cell subsets in freshly isolated bovine leukocytes by flow cytometry. The 1D10F1 mAb recognized PD-1 expressed on CD3⁺, CD3⁺CD4⁺, CD3⁺CD8⁺, and CD3⁺γδTCR⁺ T cells, whereas 4F5F2 did not (Figure 1B). The detection sensitivity of PD-1 on the T-cell subsets by 1D10F1 was higher compared with the previously established mAb 5D2 (Figures 1B and C). Therefore, 1D10F1 has high sensitivity for the detection of bovine PD-1 in flow cytometry.

To analyze the inhibitory activity of 1D10F1 and 4F5F2, the effect of the mAbs in a binding assay with BoPD-1-Ig to BoPD-L1-EGFP expressing cells was determined by flow cytometry compared with 5D2. 1D10F1, 4F5F2 and 5D2 inhibited PD-1/PD-L1 binding in a dose-dependent manner (Figure 1D). At 50 μg/mL, the 1D10F1, 4F5F2, and 5D2 mAbs inhibited 79.2%, 54.6%, and 44.4% of PD-1/PD-L1 binding, respectively (Figure 1D). Based on these results, the mAb 1D10F1 was considered as the best blocking antibody among the established anti-bovine PD-1 mAbs.

Establishment of an anti-bovine PD-1 rabbit-bovine chAb

The rabbit mAb 1D10F1 was engineered into a rabbit-bovine chAb, Boch1D10F1. To obtain a large amount of Boch1D10F1 for further in vitro and in vivo characterization, Boch1D10F1 was stably expressed and produced using the CHO DG44 cell expression system. Three plasmids were evaluated as an expression vector for Boch1D10F1. UCOE reduces DNA methylation in a transgene promoter and contributes to the maintenance of the expression of recombinant proteins in CHO cells [22]. pDC62c5-U533 was designed with UCOEs at the 5' and 3' ends of the expression cassettes of VL+CL and VH+CH (Figure 2A). This plasmid was modified using the pDC61 expression vector for the selection of high protein expressing cell lines using thymidine-hyposanthin regulated by the selection marker DHFR (Figure 2A), which was established previously [11, 23]. In addition, the other vector (pNC32c-U533) with UCOEs with a neomycin resistance (*nept*) selection marker was used to evaluate

Table 1 Binding affinity of anti-PD-1 mAbs to BoPD-1-His protein

Anti-PD-1 mAb	k_a (1/Ms)	k_d (1/s)	KD (M)
5D2**	$1.84 \times 10^4 \pm 0.27$	$2.15 \times 10^{-4} \pm 0.44$	$1.22 \times 10^{-8} \pm 0.39$
1D10F1	$1.63 \times 10^6 \pm 0.16^*$	$1.80 \times 10^{-3} \pm 0.06^*$	$1.11 \times 10^{-9} \pm 0.07^*$
4F5F2	$7.39 \times 10^5 \pm 0.90^*$	$2.08 \times 10^{-3} \pm 0.28^*$	$2.85 \times 10^{-9} \pm 0.50^*$

These values were measured on a Biacore X100 instrument

* $p < 0.05$ (vs. 5D2; Tukey's test)

** The values for 5D2 were shown in a previous paper [10]




Figure 1 Generation and characterization of anti-bovine PD-1 rabbit mAbs. **A** Flow cytometric analysis using anti-bovine PD-1 rabbit mAbs (1D10F1 and 4F5F2) and anti-bovine PD-1 rat mAb (5D2). BoPD-1-myc cells were stained with the mAbs using serial dilutions (10 µg/mL to 100 pg/mL). Rat IgG_{2a} isotype control and rabbit IgG controls (1H4L and 4H1L) were used as negative controls. **B, C** Flow cytometric analysis of PD-1 expression in T-cell subsets of cattle ($n = 3$). Freshly isolated bovine PBMCs were stained with anti-bovine PD-1 rabbit mAbs (1D10F1 and 4F5F2) and anti-bovine PD-1 rat mAb (5D2). Rat IgG_{2a} isotype control and rabbit IgG control (1H4L) were used as negative controls. **B** Representative histograms of staining with anti-PD-1 mAbs (orange, green, or blue histograms) and matched negative controls (gray histograms) are shown. The gating strategy of this assay was provided as Additional file 3. **C** Percentages of PD-1⁺ cells in each T-cell subset in leukocytes from healthy cattle ($n = 3$). Bars indicate the group mean percentage. Significant differences between each of the two groups were determined using a Student's t test. $*p < 0.05$. **D** BoPD-1-Ig was preincubated with anti-bovine PD-1 rabbit mAbs (1D10F1 and 4F5F2) and anti-bovine PD-1 rat mAb (5D2), and then reacted with BoPD-L1-EGFP cells. BoPD-1-Ig bindings were evaluated by flow cytometry. Rat IgG_{2a} and rabbit IgG controls (1H4L and 4H1L) were used as negative controls. Each curve represents the relative binding of BoPD-1-Ig preincubated with each antibody compared with the no-antibody control.

the performance of the combination of UCOEs and the DHFR selection marker (Figure 2A) [10, 23]. More than 100 clones were randomly selected from the cloned CHO DG44 cells transfected with each plasmid and examined for their Boch1D10F1 production by ELISA. Cells transfected with pDC62c5-U533-Boch1D10F1, pDC61-Boch1D10F1, and pNC32c-U533-Boch1D10F1 stably produced 62.2, 41.8, and 4.10 $\mu\text{g/mL}$ of Boch1D10F1 after three days of shaking culture (Figure 2B). In particular, 22.6% (24/106 clones), 1.8% (2/112 clones), and 0% (0/105 clones), respectively, of the established cell lines transfected with pDC62c5-U533-Boch1D10F1, pDC61-Boch1D10F1, and pNC32c-U533-Boch1D10F1 were among the higher-producing cell lines producing $> 20 \mu\text{g/mL}$ protein (Figure 2B). Thus, pDC62c5-U533 was selected for the production of recombinant antibody because high-expressing cells could be obtained efficiently.

To produce large amounts of Boch1D10F1, one of the higher Boch1D10F1-producing cell lines was cultured in 2 L of shaking culture using Dynamis Medium. Boch1D10F1 was present in the supernatants at 623.5 mg/L after 14 days (Figure 2C) and successfully purified using Protein A resin (Figure 2D). The heavy and light chains of Boch1D10F1 were detected at approximately 50 and 25 kDa under reducing conditions, respectively (Figure 2B). Under nonreducing conditions, Boch1D10F1 was detected as a pure, single band at $> 150 \text{ kDa}$, which suggests that the antibody consists of two heavy and two light chains. Thus, mass production of Boch1D10F1 was achieved using a mammalian expression system.

Characterization of anti-bovine PD-1 rabbit-bovine chAb

The binding ability of Boch1D10F1 was determined by flow cytometry using bovine PD-1-expressing cells (BoPD-1-myc cells). Boch1D10F1 was bound to BoPD-1-myc cells in a dose-dependent manner (Figure 3A). To confirm the binding affinity of Boch1D10F1 to bovine PD-1 protein, SPR analysis was performed using a Biacore 3000 instrument with BoPD-1-His protein. Boch1D10F1 and the original 1D10F1 rabbit mAb had a similar affinity for PD-1, with K_D values of 1.23 ± 0.05 and $1.37 \pm 0.09 \text{ nM}$, respectively (Table 2). Therefore, the chimerization of anti-PD-1 antibody did not alter its binding affinity to bovine PD-1 protein.

To analyze the blocking activity of Boch1D10F1, the binding of BoPD-1-Ig to BoPD-L1-EGFP-expressing cells was determined in the presence of Boch1D10F1, 1D10F1, Boch5D2, and 5D2 by flow cytometry. Boch1D10F1 inhibited the binding of PD-1/PD-L1 in a dose-dependent manner at a level similar to that of 1D10F1 (Figure 3B). In contrast, Boch5D2 and 5D2 exhibited a partial blockade of the PD-1/PD-L1 interaction (Figure 3B).

Thus, Boch1D10F1 is capable of robustly inhibiting the binding of bovine PD-1/PD-L1.

The T-cell response of BLV-infected cattle is impaired by the interaction of PD-1/PD-L1 [6–8, 11]. To determine whether the treatment of Boch1D10F1 reactivates the T-cell response of BLV-infected cattle, IFN- γ production was analyzed in a cultivation assay containing PBMCs from BLV-infected cattle in the presence of Boch1D10F1 and viral antigen stimulation. The Boch1D10F1 blockade significantly enhanced IFN- γ production by PBMCs (Figure 3C), even though Boch5D2 also activated a significant IFN- γ response (Figure 3D). These results suggest that Boch1D10F1 has the potential to enhance the T-cell response in cattle.

Reduction of proviral load by the treatment of BLV-infected cattle with Boch1D10F1

To evaluate the antiviral effect of Boch1D10F1 in vivo, BLV-infected cattle were inoculated with anti-PD-1 chAb (Boch1D10F1). AL2 and PL2 were treated with Boch1D10F1 intravenously at a dose of 1 or 2 mg/kg, respectively. AL3 and PL3 also received an intravenous dose of Boch1D10F1 (1 or 2 mg/kg) on day 0 as well as a subcutaneous injection of 0.5 mg/kg meloxicam (Metacam) on day 0, 7, and 14, because the combination of PD-1/PD-L1 blockade and COX-2 inhibition represents a promising strategy to synergistically enhance the antiviral T-cell response during BLV infection [12, 30]. Among the treated animals, AL2 and PL3 exhibited a sustained decrease in BLV proviral load in PBMCs following Boch1D10F1 administration (Figure 4).

Discussion

In this study, two high-affinity rabbit mAbs (1D10F1 and 4F5F2) against bovine PD-1 were successfully generated. The mAb 1D10F1 was very useful for the detection of bovine PD-1 in immunostaining for flow cytometry and exhibited strong inhibition of the PD-1/PD-L1 interaction, compared with the rat mAb 5D2. In contrast, 4F5F2 was also expected to be a good detection antibody because of its high binding affinity to the extracellular region of the PD-1 soluble protein (BoPD-1-His) in the Biacore assay (Table 1), but flow cytometric assays with this mAb detected a smaller percentage of full-length PD-1 protein in BoPD-1-myc overexpressing cells (Figure 1A) and none at all in bovine T cells (Figure 1B). This is presumably because the epitope to which 4F5F2 binds could be a motif not exposed on the surface of full-length PD-1 protein expressed at plasma membrane. More validation is needed to explain well why the seemingly contradictory results were obtained for 4F5F2.




Figure 2 Production of anti-PD-1 chimeric antibody, Boch1D10F1. **A** Schematic structures of plasmid vectors encoding Boch1D10F1 (pDC62c5-U533-Boch1D10F1, pDC61-Boch1D10F1, and pNC32c-U533-Boch1D10F1). The light chain consisting of a variable region (VL) and a constant region (CL). The heavy chain consisting of a variable region (VH) and a constant region (CH). mDHFR: modified dihydrofolate reductase, UCOE: ubiquitous chromatin opening element (UCOE), npt: neomycin-resistant gene. **B** Selection of CHO DG44 cell clones producing Boch1D10F1. The production capacity of Boch1D10F1 from each cell clone transfected with pDC62c5-U533-Boch1D10F1 (blue bars), pDC61-Boch1D10F1 (red bars), and pNC32c-U533-Boch1D10F1 (green bars) are shown. The production capacity of the highest producing clones for each vector are shown in the plot. **C** Expression of Boch1D10F1. Boch1D10F1 was expressed in 2L of shaking culture of a higher-producing cell line. The antibody production (left axis: gray bar) and the density of live and dead cells (right axis: black and white circles) were measured at 3- to 4-day intervals. **D** Purification of Boch1D10F1. Boch1D10F1 was purified from the supernatants of shaking cultures. Purified protein was confirmed by reducing and nonreducing SDS-PAGE. An uncropped gel image generated during the current study is provided in Additional file 4.




Figure 3 Characterization of Boch1D10F1. **A** Reactivity of Boch1D10F1 with BoPD-1-myc cells. BoPD-1-myc cells were stained with Boch1D10F1 in serial dilutions (10 µg/mL to 100 pg/mL) and analyzed by flow cytometry. **B** Blockade of PD-1/PD-L1 binding by Boch1D10F1. BoPD-1-Ig was preincubated with 5D2 and Boch5D2 and incubated with BoPD-L1-EGFP cells. BoPD-1-Ig bindings were evaluated by flow cytometry. Each curve represents the relative binding of BoPD-1-Ig preincubated with Boch1D10F1, Boch5D2, 1D10F1, and 5D2 compared with no-antibody control. Bovine IgG (for Boch1D10F1 and Boch5D2), rabbit IgG (1H4L), and rat IgG_{2a} controls (for 5D2) were used as negative controls. **C, D** Effect of PD-1/PD-L1 blockade on the IFN-γ response. PBMCs of BLV-infected cattle ($n = 13$) were cultured with Boch1D10F1 and Boch5D2 (10 µg/mL) or bovine IgG control in the presence of FLK-BLV antigen (2%) for 6 days. IFN-γ production for each animal was measured by ELISA in duplicate. Bars indicate the group median response. Significant differences between each group were determined using Wilcoxon signed-rank test Friedman test. ** $p < 0.01$.

Table 2 Binding affinity of anti-PD-1 rabbit mAb and chAb to BoPD-1-His protein

Anti-PD-1 antibody	ka (1/Ms)*	kd (1/s)*	KD (M)*
1D10F1	$5.00 \times 10^5 \pm 0.29$	$6.17 \times 10^{-4} \pm 0.38$	$1.23 \times 10^{-9} \pm 0.05$
Boch1D10F1	$4.37 \times 10^5 \pm 0.09$	$6.13 \times 10^{-4} \pm 0.61$	$1.37 \times 10^{-9} \pm 0.09$

These values were measured on a Biacore 3000 instrument

* The values of 1D10F1 and Boch1D10F1 are not significantly different ($p > 0.05$)

We have been working on the establishment and characterization of bovine chAb [10, 11, 31], and this study represents our first attempt at establishing a rabbit–bovine chAb to achieve increased binding affinity to an antigen. The anti-PD-1 rabbit–bovine chAb (Boch1D10F1) was generated in a high-producing cell line selected from more than 300 cell clones. As reported previously, the addition of UCOE into the expression plasmid also increased the expression level of the transgene compared with conventional plasmids in our experiments. Although we have not examined the mechanism of this increase, UCOE is known to inhibit DNA methylation in the transgene promoter and maintain the expression level of the transgene after many passages of the established cell line [22, 23]. In the present study, Boch1D10F1 was prepared for animal experiments using adult cattle in a flask-shaking culture system. We established as system to develop a higher antibody producing cell line, which will be very useful for in vivo antibody research using large animal models, such as cattle, dogs, pigs, horses, and monkeys.

Although Boch1D10F1 exhibited a higher binding affinity and stronger blocking activity to bovine PD-1 compared with Boch5D2 [10], immune activating efficacy was observed in PBMC cultivation assays using these chAbs. IFN- γ was measured as a representative cytokine as well as a key regulator of Th1 response based on our previous studies [7, 8, 10]. We attempted to measure other cytokines, such as IL-2 and TNF- α using ELISA, but they were not detectable in the culture supernatant. To determine the blockade effect in EBL animals, other methods to detect cytokine production from BLV-specific T cells are needed, such as the Enzyme-Linked ImmunoSpot Assay or Luminex Assay System with immunogenic peptides or proteins [32–34].


With the spread of BLV on farms throughout Japan [35], the incidence of EBL has increased in recent years, causing significant economic losses for dairy and beef farmers. Because of the high prevalence in Japan, it has been extremely difficult to implement cleanup through the detection and culling of infected cattle. Furthermore, no effective treatment or vaccine has become

commercially available at this time. Therefore, a novel control strategy against BLV infection is required.

In the animal experiment of Boch1D10F1 administration, PD-1 blockade reduced the BLV proviral load in one of the aleukemic (AL) cattle (AL2), which is consistent with a previous observation in a pilot clinical trial of Boch5D2 [10]. The antiviral effect in this animal was observed throughout the experiment. In contrast, a continuous antiviral effect was not observed in PL2, which is also consistent with our previous study demonstrating that PD-1/PD-L1 and COX-2/prostaglandin E2 (PGE₂) pathways cooperatively suppresses the T-cell response in BLV-infected cattle with progressive disease, such as persistent lymphocytosis (PL) animals [12]. Consistently, the combination of Boch1D10F1 and meloxicam induced an antiviral effect in a PL cow (PL3); however, the viral load was reversed at day 49 post-administration. The mechanism of this increase may be a decreased blocking effect resulting from antibody degradation or compensation by other immunosuppressive factors, such as the immune checkpoint molecule, cytotoxic T-lymphocyte antigen 4 (CTLA-4), or regulator T-cell subsets [36–38]. These possibilities should be tested in subsequent clinical studies through repeated administration of chAb or a combination with other blocking antibodies, such as anti-CTLA-4 chAb [31]. In addition, phenotyping T-cell subsets in these animals will be important to understand the varying efficacy of PD-1 blockade observed in each individual.

We demonstrated that treatment with anti-PD-L1 chAb activated the T-cell response in cattle infected with *Mycobacterium avium* subsp. *paratuberculosis* and *Mycoplasma bovis* [39–41]. The clinical benefit of Boch1D10F1 treatment may also be determined in cattle with paratuberculosis and mycoplasmosis anaplasmosis to determine whether targeting PD-1/PD-L1 pathway can be applied as broad-spectrum immunotherapy against chronic infectious diseases in cattle. In addition, functional role of PD-1/PD-L1 pathway in T-cell response of other bovine infections should be clarified, such as bovine tuberculosis, brucellosis, babesiosis, and theileriosis to consider the spectrum of this strategy. Furthermore, bovinized antibodies, in which the frameworks of the variable region are replaced with bovine antibody, are expected to improve stability in vivo and further enhance clinical efficacy and could be the next option of the strategy for bovine immunotherapy.

To develop new control methods for chronic infectious diseases, it is necessary to further analyze the immunosuppressive mechanisms of each disease and to consider



* $p < 0.05$ (vs. pre-administration)

Figure 4 Effect on proviral loads on BLV-infected cattle administered Boch1D10F1. Provirus copy number per 50 ng DNA of PBMCs from BLV-infected cattle administered Boch1D10F1 with or without meloxicam (Metacam). Proviral loads of BLV were quantified in PBMCs at each time point by real-time genomic PCR targeting the BLV *tax* gene. Each dot represents the mean of three independent experiments. Significant differences were determined by Dunnett's multiple-comparison test across the time points. * $p < 0.05$ versus pre-administration. AL: aleukemic, PL: persistent lymphocytosis.

the most effective combination of therapies (therapeutic targets). In addition, the development and production costs of antibody drugs must be fully considered. This study provides a technological basis for producing high performance antibodies in large quantities and at low cost.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13567-023-01213-6>.

Additional file 1. Animals used in the experiment of antibody administration. Six BLV-infected cattle (Holstein, female) were used for the administration experiments of Boch1D10F1 and meloxicam to evaluate their antiviral effects *in vivo*.

Additional file 2. Flow cytometric analysis using anti-bovine PD-1 mAbs to mock cells. Flow cytometric analysis was performed using anti-bovine PD-1 rabbit mAbs (1D10F1 and 4F5F2) and anti-bovine PD-1 rat mAb (5D2) and mock-transfected CHO DG44 cells. CHO DG44 cells were transfected with pCI-neo (mock plasmid) and cloned by limiting dilution. The mock cell line was stained with the mAbs (100 µg/mL) at room temperature for 30 min. Rat IgG_{2a} isotype control and rabbit IgG controls (1H4L and 4H1L) were used as negative controls. The cells were labeled with Alexa Flour 647-conjugated anti-rabbit IgG (H + L) goat F(ab')₂ (Thermo Fisher Scientific), APC-conjugated anti-rat immunoglobulin antibody (Southern Biotech) at room temperature for 30 min. Finally, the cells were washed and analyzed immediately using FACS Verse (BD Biosciences).

Additional file 3. Gating strategy of T-cell subsets in leukocytes from healthy cattle. CD4⁺, CD8⁺, or γδTCR⁺ T cells were gated in CD3⁺IgM⁻ lymphocytes and then analyzed for expression of PD-1 in each T cell subset as shown in Figure 1B.

Additional file 4. An uncropped gel image for Figure 2 D. Purified anti-PD-1 chAb (Boch1D10F1) was analyzed by reducing and nonreducing SDS-PAGE.

Acknowledgements

We are grateful to Dr Hideyuki Takahashi, Dr Yasuyuki Mori, and Dr Tomio Ibayashi for their valuable advice and discussions, and the technical staffs of the animal facilities for the excellent care and handling of animals. We thank Enago for the English language review.

Authors' contributions

Conceptualization: TO, SK, YSu, KO; Investigation: TO, SK, SG, YSa, OG, KW, HN, CXW, YuK, YaK, JK, NT, HT; Analysis and interpretation of data: TO, SK, SG, TT, YuK, JK, MK, AT, YSu, NM, SM; Methodology and resources: YuK, JK, TT, MK, YSu, NM; Supervision: SK, SM, KO; Writing original draft: TO, SK; Review and editing: SG, YaS, CXW, TT, YuK, JK, NT, MK, AT, HT, YSu, NM, SM, KO. All authors read and approved the final manuscript.

Funding

This work was supported by JSPS KAKENHI grant number 19KK0172, 22H02503, 22K19232 [to S.K.], 19K15993, and 22K15005 [to T.O.], grants from the Project of the NARO, Bio-oriented Technology Research Advancement Institution (Research Program on Development of Innovative Technology 26058 BC [to S.K.] and Special Scheme Project on Regional Developing Strategy, Grant 16817557 [to S.K.]), grants from Ito Memorial Foundation [to S.K.] and Regulatory Research Projects for Food Safety, Animal Health and Plant Protection (JPJ008617.17935709 [to S.K.]) and supported by the Japan Agency for Medical Research and Development (AMED) under Grants JP223fa627005 [to S.K.], JP21am0101078 [to Y.K.] and JP22ama121008 [to Y.K.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This animal experiment was approved by the Ethics Committee of the Animal Research Center, Agricultural Research Department, Hokkaido Research Organization (approval # 1703) and the Ethics Committee of the Faculty of Veterinary Medicine, Hokkaido University (Approval #17-0024).

Competing interests

YSu, YK, SK, TO, NM, SG, YSa, KO, and SM have a patent pending for materials and techniques described in this paper (Japanese patent, Application number 2018-99704).

Author details

¹Department of Advanced Pharmaceuticals, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan. ²Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan. ³Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan. ⁴Department of Bioengineering, Graduate School of Engineering, Osaka City University, Osaka, Japan. ⁵Department of Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, Osaka, Japan. ⁶Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan. ⁷Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan. ⁸Division of Biore-sources, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan. ⁹Animal Research Center, Agriculture Research Department, Hokkaido Research Organization, Shintoku, Japan. ¹⁰Hokkaido Agricultural Mutual Aid Association, Shibecha, Japan. ¹¹Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan. ¹²International Affairs Office, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.

Received: 12 December 2022 Accepted: 2 September 2023

Published online: 27 September 2023

References

- Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ (2009) Coregulation of CD8⁺ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nat Immunol* 10:29–37. <https://doi.org/10.1038/ni.1679>
- Khaitan A, Unutmaz D (2011) Revisiting immune exhaustion during HIV infection. *Curr HIV/AIDS Rep* 8:4–11. <https://doi.org/10.1007/s11904-010-0066-0>
- Wherry EJ (2011) T cell exhaustion. *Nat Immunol* 12:492–499. <https://doi.org/10.1038/ni.2035>
- Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol* 15:486–499. <https://doi.org/10.1038/nri3862>
- Ikebuchi R, Konnai S, Sunden Y, Onuma M, Ohashi K (2010) Molecular cloning and expression analysis of bovine programmed death-1. *Microbiol Immunol* 54:291–298. <https://doi.org/10.1111/j.1348-0421.2010.00208.x>
- Ikebuchi R, Konnai S, Shirai T, Sunden Y, Murata S, Onuma M, Ohashi K (2011) Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses *in vitro* via PD-L1 blockade. *Vet Res* 42:103. <https://doi.org/10.1186/1297-9716-42-103>
- Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, Suzuki Y, Murata S, Ohashi K (2013) Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells *in vitro*. *Vet Res* 44:59. <https://doi.org/10.1186/1297-9716-44-59>

8. Okagawa T, Konnai S, Nishimori A, Maekawa N, Goto S, Ikebuchi R, Kohara J, Suzuki Y, Yamada S, Kato Y, Murata S, Ohashi K (2018) Cooperation of PD-1 and LAG-3 in the exhaustion of CD4⁺ and CD8⁺ T cells during bovine leukemia virus infection. *Vet Res* 49:50. <https://doi.org/10.1186/s13567-018-0543-9>
9. Schwartz I, Levy D (1994) Pathobiology of bovine leukemia virus. *Vet Res* 25:521–536
10. Okagawa T, Konnai S, Nishimori A, Maekawa N, Ikebuchi R, Goto S, Nakajima C, Kohara J, Ogasawara S, Kato Y, Suzuki Y, Murata S, Ohashi K (2017) Anti-bovine programmed death-1 rat-bovine chimeric antibody for immunotherapy of bovine leukemia virus infection in cattle. *Front Immunol* 8:650. <https://doi.org/10.3389/fimmu.2017.00650>
11. Nishimori A, Konnai S, Okagawa T, Maekawa N, Ikebuchi R, Goto S, Sajiki Y, Suzuki Y, Kohara J, Ogasawara S, Kato Y, Murata S, Ohashi K (2017) In vitro and in vivo antiviral activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. *PLoS One* 12:e0174916. <https://doi.org/10.1371/journal.pone.0174916>
12. Sajiki Y, Konnai S, Okagawa T, Nishimori A, Maekawa N, Goto S, Watarai K, Minato E, Kobayashi A, Kohara J, Yamada S, Kaneko MK, Kato Y, Takahashi H, Terasaki N, Takeda A, Yamamoto K, Toda M, Suzuki Y, Murata S, Ohashi K (2019) Prostaglandin E2-induced immune exhaustion and enhancement of antiviral effects by anti-PD-L1 antibody combined with COX-2 inhibitor in bovine leukemia virus infection. *J Immunol* 203:1313–1324. <https://doi.org/10.4049/jimmunol.1900342>
13. Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, Ni H, Chen B, Xiong Y, Liu Y, Peng B, Yu D, Jiang H, Liu J (2019) Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. *MAbs* 11:1443–1451. <https://doi.org/10.1080/19420862.2019.1654303>
14. Issafiras H, Fan S, Tseng CL, Cheng Y, Lin P, Xiao L, Huang YJ, Tu CH, Hsiao YC, Li M, Chen YH, Ho CH, Li O, Wang Y, Chen S, Ji Z, Zhang E, Mao YT, Liu E, Yang S, Jiang W (2021) Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. *PLoS One* 16:0257972. <https://doi.org/10.1371/journal.pone.0257972>
15. Okagawa T, Konnai S, Nishimori A, Ikebuchi R, Mizorogi S, Nagata R, Kawaji S, Tanaka S, Kagawa Y, Murata S, Mori Y, Ohashi K (2016) Bovine immunoinhibitory receptors contribute to the suppression of *Mycobacterium avium* subsp. *paratuberculosis*-specific T-cell responses. *Infect Immun* 84:77–89. <https://doi.org/10.1128/IAI.01014-15>
16. Okagawa T, Konnai S, Deringer JR, Ueti MW, Scoles GA, Murata S, Ohashi K, Brown WC (2016) Cooperation of PD-1 and LAG-3 contributes to T-cell exhaustion in *Anaplasma marginale*-infected cattle. *Infect Immun* 84:2779–2790. <https://doi.org/10.1128/IAI.00278-16>
17. Sajiki Y, Konnai S, Okagawa T, Nishimori A, Maekawa N, Goto S, Ikebuchi R, Nagata R, Kawaji S, Kagawa Y, Yamada S, Kato Y, Nakajima C, Suzuki Y, Murata S, Mori Y, Ohashi K (2018) Prostaglandin E2 induction suppresses the Th1 immune responses in cattle with John's disease. *Infect Immun* 86:e00910-17. <https://doi.org/10.1128/IAI.00910-17>
18. Weber J, Peng H, Rader C (2017) From rabbit antibody repertoires to rabbit monoclonal antibodies. *Exp Mol Med*. 49:e305. <https://doi.org/10.1038/emm.2017.23>
19. Huang B, Yin Y, Lu L, Ding H, Wang L, Yu T, Zhu JJ, Zheng XD, Zhang YZ (2010) Preparation of high-affinity rabbit monoclonal antibodies for ciprofloxacin and development of an indirect competitive ELISA for residues in milk. *J Zhejiang Univ Sci B* 11:812–818. <https://doi.org/10.1631/jzus.B1000055>
20. Miller DL, Potempska A, Wegiel J, Mehta PD (2011) High-affinity rabbit monoclonal antibodies specific for amyloid peptides amyloid-β40 and amyloid-β42. *J Alzheimer's Dis* 23:293–305. <https://doi.org/10.3233/JAD-2010-101341>
21. Warren PD, Dodson MS, Smith MH, Landowski TH, Palting JD, Towne P (2022) High-resolution epitope mapping and affinity binding analysis comparing a new anti-human LAG3 rabbit antibody clone to the commonly used mouse 17B4 clone. *Antibodies* 11:60. <https://doi.org/10.3390/antib11040060>
22. Saunders F, Sweeney B, Antoniou MN, Stephens P, Cain K (2015) Chromatin function modifying elements in an industrial antibody production platform—comparison of UCOE, MAR, STAR and chS4 elements. *PLoS One* 10:e0120096. <https://doi.org/10.1371/journal.pone.0120096>
23. Suzuki Y, Nakagawa M, Kameda Y, Konnai S, Okagawa T, Maekawa N, Goto S, Sajiki Y, Ohashi K, Murata S, Kitahara Y, Yamamoto K (2020) Novel vector and use thereof. US patent application No. 17/054,936
24. Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, Suzuki Y, Murata S, Ohashi K (2014) Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. *Immunology* 142:551–561. <https://doi.org/10.1111/imm.12243>
25. Kuo MC, Sogn JA, Max EE, Kindt TJ (1985) Rabbit-mouse hybridomas secreting intact rabbit immunoglobulin. *Mol Immunol* 22:351–359. [https://doi.org/10.1016/0161-5890\(85\)90119-1](https://doi.org/10.1016/0161-5890(85)90119-1)
26. Raman C, Spieker-Polet H, Yam PC, Knight KL (1994) Preferential VH gene usage in rabbit Ig-secreting heterohybridomas. *J Immunol* 152:3935–3945
27. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 108:193–199. [https://doi.org/10.1016/0378-1119\(91\)90434-D](https://doi.org/10.1016/0378-1119(91)90434-D)
28. Ann SS, Breuer W, Hermanns W (1996) Immunohistochemical examination of light-chain expression (lambda/kappa ratio) in canine, feline, equine, bovine, porcine plasma cells. *Zentralbl Veterinarmed A* 43:573–576. <https://doi.org/10.1111/j.1439-0442.1996.tb00489.x>
29. Mazengera KE, Kennedy BW, Burnside EB, Wilkie BN, Burton JH (1985) Genetic parameters of bovine serum immunoglobulins. *J Dairy Sci* 68:2309–2314. [https://doi.org/10.3168/jds.S0022-0302\(85\)81104-8](https://doi.org/10.3168/jds.S0022-0302(85)81104-8)
30. Sajiki Y, Konnai S, Cai Z, Takada K, Okagawa T, Maekawa N, Fujisawa S, Kato Y, Suzuki Y, Murata S, Ohashi K (2020) Enhanced immunotherapeutic efficacy of anti-PD-L1 antibody in combination with an EP4 antagonist. *Immunohorizons* 4:837–850. <https://doi.org/10.4049/immunohorizons.2000089>
31. Watarai K, Konnai S, Okagawa T, Maekawa N, Sajiki Y, Kato Y, Suzuki Y, Murata S, Ohashi K (2022) Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies. *J Vet Med Sci* 84:6–15. <https://doi.org/10.1292/jvms.21-0552>
32. Han S, Norimine J, Palmer GH, Mwangi W, Lahmers KK, Brown WC (2008) Rapid deletion of antigen-specific CD4⁺ T cells following infection represents a strategy of immune evasion and persistence for *Anaplasma marginale*. *J Immunol* 181:7759–7769. <https://doi.org/10.4049/jimmunol.181.11.7759>
33. Maggioni MF, Palmer MV, Vordermeier HM, Whelan AO, Fosse JM, Nonnecke BJ, Waters WR (2015) Application of long-term cultured interferon-γ enzyme-linked immunospot assay for assessing effector and memory T cell responses in cattle. *J Vis Exp*. 101:e52833. <https://doi.org/10.3791/52833>
34. Lawson S, Lunney J, Zuckermann F, Osorio F, Nelson E, Welbon C, Clement T, Fang Y, Wong S, Kulas K, Christopher-Hennings J (2010) Development of an 8-plex Luminex assay to detect swine cytokines for vaccine development: assessment of immunity after porcine reproductive and respiratory syndrome virus (PRRSV) vaccination. *Vaccine* 28:5356–5364. <https://doi.org/10.1016/j.vaccine.2010.05.016>
35. Murakami K, Kobayashi S, Konishi M, Kameyama K, Tsutsui T (2013) Nationwide survey of bovine leukemia virus infection among dairy and beef breeding cattle in Japan from 2009–2011. *J Vet Med Sci* 75:1123–1126. <https://doi.org/10.1292/jvms.12-0374>
36. Suzuki S, Konnai S, Okagawa T, Ikebuchi R, Shirai T, Sunden Y, Mingala CN, Murata S, Ohashi K (2013) Expression analysis of Foxp3 in T cells from bovine leukemia virus infected cattle. *Microbiol Immunol* 57:600–604. <https://doi.org/10.1111/1348-0421.12073>
37. Suzuki S, Konnai S, Okagawa T, Ikebuchi R, Nishimori A, Kohara J, Mingala CN, Murata S, Ohashi K (2015) Increased expression of the regulatory T cell-associated marker CTLA-4 in bovine leukemia virus infection. *Vet Immunol Immunopathol* 163:115–124. <https://doi.org/10.1016/j.vetimm.2014.10.006>
38. Ohira K, Nakahara A, Konnai S, Okagawa T, Nishimori A, Maekawa N, Ikebuchi R, Kohara J, Murata S, Ohashi K (2016) Bovine leukemia virus reduces anti-viral cytokine activities and NK cytotoxicity by inducing TGF-β secretion from regulatory T cells. *Immunity, Inflamm Dis* 4:52–63. <https://doi.org/10.1002/iid3.93>

39. Sajiki Y, Konnai S, Nagata R, Kawaji S, Nakamura H, Fujisawa S, Okagawa T, Maekawa N, Kato Y, Suzuki Y, Murata S, Mori Y, Ohashi K (2021) The enhancement of th1 immune response by anti-pd-l1 antibody in cattle infected with *Mycobacterium avium* subsp. *paratuberculosis*. *J Vet Med Sci* 83:162–166. <https://doi.org/10.1292/jvms.20-0590>
40. Goto S, Konnai S, Hirano Y, Kohara J, Okagawa T, Maekawa N, Sajiki Y, Watari K, Minato E, Kobayashi A, Gondaira S, Higuchi H, Koiwa M, Tajima M, Taguchi E, Uemura R, Yamada S, Kaneko MK, Kato Y, Yamamoto K, Toda M, Suzuki Y, Murata S, Ohashi K (2020) Upregulation of PD-L1 expression by prostaglandin E2 and the enhancement of IFN- γ by anti-PD-L1 antibody combined with a COX-2 inhibitor in *Mycoplasma bovis* Infection. *Front Vet Sci* 7:12. <https://doi.org/10.3389/fvets.2020.00012>
41. Goto S, Konnai S, Hirano Y, Kohara J, Okagawa T, Maekawa N, Sajiki Y, Watari K, Minato E, Kobayashi A, Gondaira S, Higuchi H, Koiwa M, Tajima M, Taguchi E, Ishida M, Uemura R, Yamada S, Kaneko MK, Kato Y, Yamamoto K, Toda M, Suzuki Y, Murata S, Ohashi K (2020) Clinical efficacy of the combined treatment of anti-PD-L1 rat-bovine chimeric antibody with a cox-2 inhibitor in calves infected with *Mycoplasma bovis*. *Jpn J Vet Res* 68:77–90. <https://doi.org/10.14943/jjvr.68.2.77>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

